Compass' psychedelic-based depression treatment scores second late-stage study win

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...
Fierce Biotech

Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass gains as psychedelic therapy succeeds in late-stage trial for depression

Compass Pathways (CMPS) added ~20% in the premarket on Tuesday after the U.K.-based biotech announced that its psychedelic ...

Compass Pathways' depression treatment meets main goal in late‑stage study

Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy reduced the severity of symptoms in a late-stage study, sending its shares up nearly 23%. The ...

Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.
pharmaphorum

Compass points to strong psilocybin data in depression

The latest readout, from the COMP006 study, showed that two doses of the highest, 25 mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...
MarketWatch

Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.